Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones

Gonzalez-Ericsson, 2020, The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice, J Pathol, 250, 667, 10.1002/path.5406 Tsao, 2018, PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project, J Thorac Oncol, 13, 1302, 10.1016/j.jtho.2018.05.013 Lawson, 2020, Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies, Mod Pathol, 33, 518, 10.1038/s41379-019-0372-z Adam, 2018, Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, Ann Oncol, 29, 953, 10.1093/annonc/mdy014 Ratcliffe, 2017, Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer, Clin Cancer Res, 23, 3585, 10.1158/1078-0432.CCR-16-2375 Gaule, 2017, A quantitative comparison of antibodies to programmed cell death 1 ligand 1, JAMA Oncol, 3, 256, 10.1001/jamaoncol.2016.3015 Dodson, 2020, External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different, J Pathol Clin Res, 6, 138, 10.1002/cjp2.153 Rimm, 2017, A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer, JAMA Oncol, 3, 1051, 10.1001/jamaoncol.2017.0013 Callea, 2016, Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer immunotherapy and challenges for the pathologist: state of the art, Pathologica, 108, 48 Rebelatto, 2016, Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma, Diagn Pathol, 11, 95, 10.1186/s13000-016-0545-8 Morales-Betanzos, 2017, Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma, Mol Cell Proteomics, 16, 1705, 10.1074/mcp.RA117.000037 Stumptner, 2019, The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry, New Biotechnol, 52, 69, 10.1016/j.nbt.2019.05.003 van Seijen, 2019, Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen, Virchows Arch, 475, 191, 10.1007/s00428-019-02595-9 Lee, 2014, The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation, J Clin Pathol, 67, 573, 10.1136/jclinpath-2013-201978 Yamashita-Kashima, 2014, Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization, Gastric Cancer, 17, 638, 10.1007/s10120-013-0329-8 Forest, 2019, Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones, Virchows Arch, 475, 693, 10.1007/s00428-019-02613-w Strickland, 2020, Effects of decalcifying agents of variable duration on PD-L1 immunohistochemistry, Am J Clin Pathol, 153, 258, 10.1093/ajcp/aqz161 2018, Development and validation of a deep learning algorithm for PD-L1 scoring in tumour cells and immune cells Zajac, 2019, Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma, Diagn Pathol, 14, 99, 10.1186/s13000-019-0873-6 Pang, 2021, SP142 PD-L1 scoring shows high interobserver and intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3, Am J Surg Pathol, 45, 1108, 10.1097/PAS.0000000000001701 Cooper, 2017, Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer, Clin Cancer Res, 23, 4569, 10.1158/1078-0432.CCR-17-0151 Nielsen, 2021, Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group, J Natl Cancer Inst, 113, 808, 10.1093/jnci/djaa201 Van Bockstal, 2021, Cancers (Basel), 13, 4910, 10.3390/cancers13194910 Li, 2018, Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1, Cancer Cell, 33, 187, 10.1016/j.ccell.2018.01.009 Yin, 2019, Epidermal growth factor receptor stabilizes programmed death ligand 1 by glycosylation in colorectal cancer with microstatellite instability status, J Bio X Res, 2, 1 Ryva, 2019, Wheat germ agglutinin as a potential therapeutic agent for leukemia, Front Oncol, 9, 100, 10.3389/fonc.2019.00100 Clark, 2012, Cancer biomarker discovery: lectin-based strategies targeting glycoproteins, Dis Markers, 33, 1, 10.1155/2012/308738 Stowell, 2015, Protein glycosylation in cancer, Annu Rev Pathol, 10, 473, 10.1146/annurev-pathol-012414-040438 Karimi, 2016, Reactivity of disulfide bonds is markedly affected by structure and environment: implications for protein modification and stability, Sci Rep, 6, 10.1038/srep38572 Pace, 1996, Forces contributing to the conformational stability of proteins, FASEB J, 10, 75, 10.1096/fasebj.10.1.8566551 Koomen, 2021, Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer, Cancer Cytopathol, 129, 304, 10.1002/cncy.22383 Buonocore, 2019, CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: critical diagnostic implications, Cancer Cytopathol, 127, 643, 10.1002/cncy.22170 Gustafsson, 2015, Proteomic developments in the analysis of formalin-fixed tissue, Biochim Biophys Acta, 1854, 559, 10.1016/j.bbapap.2014.10.003 Cree, 2016, PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation, Histopathology, 69, 177, 10.1111/his.12996 Ramos-Vara, 2014, When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique, Vet Pathol, 51, 42, 10.1177/0300985813505879 Krenacs, 2010, Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections, Methods Mol Biol, 588, 103, 10.1007/978-1-59745-324-0_14 Haragan, 2020, Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry, Lab Invest, 100, 874, 10.1038/s41374-019-0366-y Lee, 2019, Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy, Cancer Cell, 36, 168, 10.1016/j.ccell.2019.06.008 Hsu, 2018, Posttranslational modifications of PD-L1 and their applications in cancer therapy, Cancer Res, 78, 6349, 10.1158/0008-5472.CAN-18-1892 Goh, 2018, Impact of host cell line choice on glycan profile, Crit Rev Biotechnol, 38, 851, 10.1080/07388551.2017.1416577 Halim, 2012, Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD, Mol Cell Proteomics, 11, 10.1074/mcp.M111.013649 Mulloy, 2009, Structural analysis of glycans Dill, 1991, Denatured states of proteins, Annu Rev Biochem, 60, 795, 10.1146/annurev.bi.60.070191.004051 Pinho, 2015, Glycosylation in cancer: mechanisms and clinical implications, Nat Rev Cancer, 15, 540, 10.1038/nrc3982 Ribbat-Idel, 2021, Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma, Front Med (Lausanne), 8 Keppens, 2021, PD-L1 immunohistochemistry in non–small-cell lung cancer: unraveling differences in staining concordance and interpretation, Virchows Arch, 478, 827, 10.1007/s00428-020-02976-5 Dressler, 2022, Deglycosylation of pathological specimens alters performance of diagnostic PDL1 antibodies, Virchows Arch, 481, 443, 10.1007/s00428-022-03369-6